Last reviewed · How we verify
ProHance
ProHance, marketed by Bracco Diagnostics, Inc., is an established MRI contrast agent with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and regulatory approval. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | ProHance |
|---|---|
| Also known as | Gadoteridol |
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) (EARLY_PHASE1)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (PHASE2)
- Intraventricular Stasis In Cardiovascular Disease
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (PHASE3)
- Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases (NA)
- Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ProHance CI brief — competitive landscape report
- ProHance updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI